Paradigm Biocapital Advisors LP Moon Lake Immunotherapeutics Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 931,480 shares of MLTX stock, worth $53.9 Million. This represents 1.69% of its overall portfolio holdings.
Number of Shares
931,480Holding current value
$53.9 Million% of portfolio
1.69%Shares
2 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.26 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$492 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$173 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$160 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$135 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $2.14B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...